Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299285 | 0.86 | CA2 (0.43) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL18322324 | 0.83 | GPR84 (0.53) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL9297272 | 0.83 | GPR84 (0.53) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL325989 | 0.83 | GPR84 (0.53) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL7148025 | 0.83 | GPR84 (0.53) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL965732 | 0.82 | CHRM1 (0.36) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL6686309 | 0.81 | GPR84 (0.52) | ACACBACACANFKB1GPR84FFAR1 | |
| Ammonia Solution, Strong SCHEMBL10519337 | 0.81 | GPR84 (0.52) | ACACBACACANFKB1GPR84FFAR1 | |
| SCHEMBL2784984 | 0.80 | TSHR (0.43) | CHRM1ADRA1AACACBACACATSHR | |
| SCHEMBL28094738 | 0.79 | CHRM1 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020239083-A1 | AEROSOL GENERATION OR SMOKING SYSTEM, OR ELECTRONIC CIGARETTE AND DEVICE THEREOF | 钟术光 | 2020-12-03 | — | — | WO | claimed |
| EP-0583171-B1 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | TAKASAGO PERFUMERY CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| EP-0374922-B1 | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | KANEGAFUCHI CHEMICAL IND (JP) | 1995-06-28 | — | — | EP | claimed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | claimed |
| US-4983759-A | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-01-08 | — | — | US | claimed |
| EP-0374922-A2 | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1990-06-27 | — | — | EP | claimed |
| US-20250275993-A1 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-04 | — | — | US | disclosed |
| WO-2020239083-A1 | AEROSOL GENERATION OR SMOKING SYSTEM, OR ELECTRONIC CIGARETTE AND DEVICE THEREOF | 钟术光 | 2020-12-03 | — | — | WO | disclosed |
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-1682527-B1 | METHOD FOR THE PRODUCTION OF STATINS | RATIOPHARM GMBH (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1888600-A2 | METHOD FOR THE PRODUCTION OF STATINS | Ratiopharm GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1288213-A4 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1288213-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1288213-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094337-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-[6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2001-12-13 | — | — | WO | disclosed |
| EP-0374922-B1 | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | KANEGAFUCHI CHEMICAL IND (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-4983759-A | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0374922-A2 | Process for the production of 3,5,6-trihydroxyhexanoic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | CHRM1 1090/4885AKR1A1 111/4885CHRM3 2792/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | CHRM1 4602/4885AKR1A1 167/4885CHRM3 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.